Taxol (Paclitaxel): A Novel Alkaloid with Anticancer Potential

Download PDF

Taxol, a widely used anticancer drug, is derived from the plant alkaloid paclitaxel. It functions as an antimicrotubular agent and a mitotic inhibitor, effectively blocking the division of cancer cells. Administered intravenously, Taxol's efficacy has been well-documented, particularly in treating solid cell tumors. Despite its success, the drug's effectiveness diminishes with prolonged use due to the development of resistance in cancer cells. Additionally, adverse effects can vary significantly based on patient-specific factors such as age, genetics, and overall health. To address these challenges, researchers have developed various conjugates, including nanocomplexes, aimed at overcoming resistance and minimizing side effects. These innovations have shown promise in enhancing the drug's therapeutic profile and extending its effectiveness. Beyond its primary role in cancer treatment, Taxol has also demonstrated potential in other therapeutic areas, broadening its clinical applications. This editorial highlights role of Taxol as an anticancer drug, emphasizing the need for continued research into overcoming resistance mechanisms and offering new avenues for this established therapeutic agent in modern oncology and beyond.